Methods of treating anemia using recombinant adeno-associated virus virions
View Patent ↗The use of recombinant adeno-associated virus (AAV) virions for delivery of DNA molecules to muscle cells and tissue in the treatment of anemia is disclosed. The invention allows for the direct, in vivo injection of recombinant AAV virions into muscle tissue, e.g., by intramuscular injection, as well as for the in vitro transduction of muscle cells which can subsequently be introduced into a subject for treatment. The invention provides for sustained, high-level expression of a delivered nucleotide sequence encoding erythropoietin, and for in vivo secretion thereof from transduced muscle cells such that systemic delivery is achieved.
1. A method of increasing the hematocrit and/or the reticulocyte count in a mammalian subject in need thereof, comprising introducing directly into a muscle cell or tissue of said subject in vivo a therapeutically effective amount of a pharmaceutical composition comprising:
(a) recombinant AAV virions which comprise an AAV vector containing a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in a host cell; and
(b) a pharmaceutically acceptable excipient;
wherein said recombinant AAV virions transduce muscle cells in said subject, and said nucleic acid molecule is expressed by said transduced cells at a level sufficient to increase the hematocrit and/or the reticulocyte count of said subject.
2. The method of claim 1 , wherein the mammalian subject has anemia.
3. The method of claim 2 , wherein the anemia is an anemic disorder selected from the group consisting of anemia associated with chronic renal failure, cancer, cancer chemotherapy and antiviral therapy.
4. The method of claim 1 , wherein the muscle cell or tissue is derived from skeletal muscle.
5. The method of claim 4 , wherein the muscle cell is a skeletal myoblast.
6. The method of claim 4 , wherein the muscle cell is a skeletal myocyte.
7. The method of claim 1 , wherein the pharmaceutical composition is administered by intramuscular injection.
8. The method of claim 7 , wherein the pharmaceutical composition is administered in a single dose.
9. The method of claim 7 , wherein the pharmaceutical composition is administered in multiple doses.
10. The method of claim 1 , wherein the nucleic acid molecule encodes native human erythropoietin.
11. The method of claim 1 , wherein the nucleic acid molecule encodes native feline erythropoietin.
12. The method of claim 1 , wherein the control elements comprise a muscle-specific promoter sequence.
13. The method of claim 1 , wherein the control elements comprise an inducible promoter sequence.
14. The method of claim 1 , wherein the recombinant AAV virions are introduced to the subject in combination with an adjunctive pharmacological therapy.
15. The method of claim 14 , wherein the adjunctive pharmacological therapy comprises administering a therapeutically effective amount of an agent selected from the group consisting of hydroxyurea, butyrate, clotrimazole, and combinations thereof.
16. The method of claim 1 , wherein the subject has a hemoglobinopathy.
17. The method of claim 16 , wherein the hemoglobinopathy is selected from the group consisting of sickle cell disease and thalassemia.
18. A method of increasing the hematocrit and/or the reticulocyte count in a mammalian subject in need thereof comprising:
(a) introducing a recombinant AAV virion into a muscle cell in vitro to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector having a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in said subject; and
(b) administering directly to muscle or tissue of said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells or tissue from step (a), wherein said nucleic acid molecule is expressed by said transduced cells at a level sufficient to increase the hematocrit and/or the reticulocyte count of said subject.
19. The method of claim 18 , wherein the mammalian subject has anemia.
20. The method of claim 19 , wherein the anemia is an anemic disorder selected from the group consisting of anemia associated with chronic renal failure, cancer, cancer chemotherapy and antiviral therapy.
21. The method of claim 19 , wherein the anemia is a hemoglobinopathy.
22. The method of claim 21 , wherein the hemoglobinopathy is selected from the group consisting of sickle cell disease and thalassemia.
23. The method of claim 18 , wherein the muscle cell is derived from skeletal muscle.
24. The method of claim 23 , wherein the muscle cell is a skeletal myoblast.
25. The method of claim 23 , wherein the muscle cell is a skeletal myocyte.
26. The method of claim 18 , wherein the nucleic acid molecule encodes native human erythropoietin.
27. The method of claim 18 , wherein the nucleic acid molecule encodes native feline erythropoietin.
28. The method of claim 18 , wherein the control elements comprise a muscle-specific promoter sequence.
29. The method of claim 18 , wherein the control elements comprise an inducible promoter sequence.
30. A method for delivering a therapeutically effective amount of erythropoietin systemically to a mammalian subject in vivo comprising introducing directly into a muscle cell or tissue of said subject a pharmaceutical composition comprising:
(a) recombinant AAV virions which comprise an AAV vector containing a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in a host cell; and
(b) a pharmaceutically acceptable excipient;
wherein said recombinant AAV virions transduce muscle cells in said subject, and said nucleic acid molecule is expressed by said transduced cells to produce a systemic level of erythropoietin sufficient to increase a hematocrit and/or a reticulocyte count of said subject.
31. The method of claim 30 , wherein the nucleic acid molecule encodes native human erythropoietin.
32. The method of claim 30 , wherein the nucleic acid molecule encodes native feline erythropoietin.
33. A method for delivering a therapeutically effective amount of erythropoietin systemically to a mammalian subject comprising:
(a) introducing a recombinant AAV virion into a muscle cell in vitro to produce a transduced muscle cell, wherein said recombinant AAV virion comprises an AAV vector having a nucleic acid molecule encoding erythropoietin operably linked to control elements that direct the transcription and translation thereof when present in said subject; and
(b) administering directly to muscle or tissue of said subject a therapeutically effective amount of a composition comprising a pharmaceutically acceptable excipient and the transduced muscle cells from step (a), wherein said nucleic acid molecule is expressed by said transduced muscle cells to produce a systemic level of erythropoietin, thereby providing for an increased hematocrit and/or reticulocyte count of said subject.
34. The method of claim 33 , wherein the nucleic acid molecule encodes native human erythropoietin.
35. The method of claim 33 , wherein the nucleic acid molecule encodes native feline erythropoietin.